Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 3,471

Document Document Title
WO/2018/008569A1
Provided is an industrially advantageous method for producing a compound (1), specifically a compound (1) in an amorphous form. A method for producing a calcium salt of a 1, 5-benzodiazepine compound represented by formula (1), which is ...  
WO/2017/215600A1
Provided are a substituted tricyclic herteocyclic compound of formula I or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt, ester or a prodrug thereof, a pharmaceutical compo...  
WO/2017/211733A1
Relating to processes for preparing suvorexant or its pharmaceutically acceptable salts through the formation of a cocrystal of (R)-benzyl 5-methyl-1,4-diazepane-1-carboxylate hydrochloridewith (R)-(+)-1,1,2-triphenyl-1,2-ethanediol ((R)...  
WO/2017/205536A2
The present invention relates to compounds of formula (I) and formula (II): and to salts thereof, wherein R1-R4 of formula (I) and R5-R6 of formula (II) have any of the values defined herein, and compositions and uses thereof. The compou...  
WO/2017/205536A3
The present invention relates to compounds of formula (I) and formula (II): and to salts thereof, and compositions and uses thereof. The compounds are useful as inhibitors of CBP and/or EP300. Also included are pharmaceutical composition...  
WO/2017/175854A1
The present invention provides a novel crystal of a compound A, the novel crystal being usable as a pharmaceutical product. Provided is a IV-type crystal of calcium (R)-(-)-3-[3-(1-tert-butylcarbonylmethyl-2-oxo-5-cyclohexyl- 1,3,4,5-tet...  
WO/2017/133620A1
The present invention relates to a synthesis process of suvorexant, and a preparation method of novel compounds represented by formulas II, III, IV or V, or a salt or intermediate thereof for preparing the suvorexant. The preparation met...  
WO/2017/063959A1
What are described are bromodomain-protein-inhibiting, especially BET protein-inhibiting and preferably BRD4-inhibiting, N-sulphoximinophenyl-substituted benzodiazepine derivatives of the general formula (I) in which R1, R2, R3, R4, and ...  
WO/2017/058915A1
Compounds having activity as inhibitors of G12C mutant KRAS protein are provided. The compounds have the following structure (I): or a pharmaceutically acceptable salt, tautomer, stereoisomer or prodrug thereof, wherein A, B R1, R2a, R2b...  
WO/2017/044849A1
The present invention provides compounds and pharmaceutically compositions thereof. The compounds and compositions are binders of bromodomains and/or bromodomain-containing proteins (e.g., bromo and extra terminal (BET) proteins). Also p...  
WO/2017/044849A8
The present invention provides compounds and pharmaceutically compositions thereof. The compounds and compositions are binders of bromodomains and/or bromodomain-containing proteins (e.g., bromo and extra terminal (BET) proteins). Also p...  
WO/2017/030859A1
The disclosure provided herein pertains to CCK2R-drug conjugates. In particular, the disclosure pertains to CCK2R-drug conjugates that target the delivery of drugs to a mammalian recipient. Also described are methods of making and using ...  
WO/2017/029567A1
A Transdermal Drug Delivery System (TDDS) of the reservoir or plaster type for administrating clobazam for the treatment of various types of anxiety and epilepsy, for 1 day, 2 day, 3 day, 4 day, 5 day, 6 day and/or 7- day continuous appl...  
WO/2017/015784A1
The present invention belongs to the field of pharmaceutical chemistry, and particularly relates to an orbit azine-fumarate, a hydrate, a crystal form and a preparation method therefor. Specifically, in the present invention, different c...  
WO/2017/005711A1
The invention relates to bromodomain-protein-inhibiting, in particular BET-protein-inhibiting, and preferably BRD4-inhibiting phosphorous- and sulfur-substituted benzodiazepine derivatives of the general formula (I), in which R1, R2, R3,...  
WO/2016/207790A1
The present application provides a one-pot catalytic process which involves the formation of 1,4-dibenzodiazepines from o-haloaldimines (either pre-formed or formed in situ) of formula (I) and o-haloanilines of formula (II) via a palladi...  
WO/2016/176138A1
Disclosed are novel bis(aminophenylphenol) ligands and transition metal compounds derived therefrom. Also disclosed are methods of making the ligands and transition metal compounds.  
WO/2016/151464A1
The present invention provides an improved process for the preparation of 8-chloro-1-phenyl- 1H-benzo[b][1,4]diazepine-2,4(3H,5H)-dione (hereafter referred to as the compound (IV)), which is useful as a key intermediate for the synthesis...  
WO/2016/146048A1
Provided is an industrial manufacturing method for a midazolam derivative, said method being characterised in that: compound A and compound B undergo a cyclisation reaction under the conditions of a catalyst. The provided production meth...  
WO/2016/146049A1
Provided is an industrial preparation method of midazolam, characterized in that a compound A and a compound B have a ring reaction under a catalyst condition. The preparation method is simple, differs from a complex production manner an...  
WO/2016/126725A1
The present disclosure relates to inhibitors of zinc-dependent histone deacetylases (HDACs) useful in the treatment of diseases or disorders associated with an HDAC, e.g., HDAC6, having a Formula I:, where R, L, X1, X2, X3, X4, Y1, Y2, Y...  
WO/2016/126722A1
The present disclosure relates to inhibitors of zinc-dependent histone deacetylases (HDACs) useful in the treatment of diseases or disorders associated with an HDAC, e.g., HDAC6, having a Formula I: (Formula I should be inserted here) wh...  
WO/2016/126721A1
The present invention relates to inhibitors of zinc-dependent histone deacetylases (HDACs) useful in the treatment of diseases or disorders associated with HDAC6, having a Formula I:(Formula I should be inserted here), where R, L, X1, X2...  
WO/2016/126724A1
The present disclosure relates to inhibitors of zinc-dependent histone deacetylases (HDACs) useful in the treatment of diseases or disorders associated with an HDAC, e.g., HDAC6, having a Formula I:(Formula I should be inserted here) whe...  
WO/2016/105448A1
This disclosure provides compounds and compositions for use as analgesics and for the treatment of various conditions, such as pain, headaches, allodynia, and fibromyalgia. The disclosure also provides compounds that are ligands, and in ...  
WO/2016/087370A1
The present invention relates to derivatives of formula (I) wherein (R1)n, ring (A), Y1, Y2, X, R4, L1, L2, and Ar1 are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use...  
WO/2016/085784A1
The present invention is directed to methyl diazepane compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neuro...  
WO/2016/062688A1
The invention relates to bromodomain protein-inhibiting, in particular BET protein-inhibiting, preferably BRD4-inhibiting carboxamides of general formula (I), in which R1, R2, R3, R4 and R5 have the meanings specified in the description,...  
WO/2016/055028A1
The present invention relates to compounds of formula (I): and to salts thereof, wherein A has any of the values defined in the specification, and compositions and uses thereof. The compounds are useful as inhibitors of CBP and/or EP300....  
WO/2016/020406A1
The present invention relates to a process for the preparation of a compound of formula (Ila') and (II) Further, the present invention relates to a compound of formula (Ila') and to a compound of formula (II) as well as all intermediates...  
WO/2016/020404A1
The present invention relates to a process for the preparation of an acid salt (T) of a compound of formula (A) (A) as well as to the acid salt (T) and the compound (A) as such,wherein R1 is selected from the group consisting of H, PG1 a...  
WO/2016/020405A1
The present invention relates to a process for the preparation of a compound of formula (A), Further, the present invention relates to the respective compound (A) as such and to its use in the preparation of antifungal agent.  
WO/2016/022902A1
The present disclosure provides compounds of Formula (I), and pharmaceutically compositions thereof. Compounds of Formula (I) have been found to bind bromodomains and/or bromodomain-containing proteins (e.g., bromo and extra terminal (BE...  
WO/2015/200766A3
The present invention provides compounds and compositions which are positive allosteric modulators of GABA-A receptors that selectively target the peripheral nervous system and organs of the body, and which do not pass through the blood-...  
WO/2015/200766A2
The present invention provides compounds and compositions which are positive allosteric modulators of GABA-A receptors that selectively target the peripheral nervous system and organs of the body, and which do not pass through the blood-...  
WO/2015/159170A3
The present invention relates to an improved and efficient process for the preparation of highly useful and versatile chiral compound (S)-(-)-l-(4-methoxyphenyl) ethylamine of formula (1) and formula (1-R) from novel chiral compounds (S)...  
WO/2015/149178A1
The present disclosure relates to a method for treating cancer comprising administering to a patient in need thereof an effective amount of a compound having the formula: (Formula (I)) wherein R1, R2, Ya, Xa, and J- are as defined herein.  
WO/2015/136557A3
The present invention provides compounds of formula (I), compositions, uses thereof and methods for inhibiting proliferation or obliterating cancer stem cells which includes killing; and/or inducing apoptosis in cancer stem cells. Includ...  
WO/2015/138500A1
A genus of arylsulfonamide derivatives of aminocycloalkanols is disclosed. The compounds are of the following genus (I):. The compounds induce FOXO1 transcription factor translocation to the nucleus by modulating PP2A and, as a consequen...  
WO/2015/121227A1
The invention relates to bromodomain protein-inhibiting, in particular BET protein-inhibiting, and preferably BRD4-inhibiting 6,9-disubstituted 2,3-benzodiazepines of general formula (I), in which R1a, R1b, R1c, R2, R3, R4, R5, R6a and R...  
WO/2015/121226A1
The invention relates to bromodomain protein-inhibiting, in particular BET protein-inhibiting, and preferably BRD4-inhibiting 6-substituted 2,3-benzodiazepines of general formula (I), in which R1a, R1b, R1c, R2, R3, R4, R5 and R6 have th...  
WO/2015/121268A1
The invention relates to bromodomain protein-inhibiting, in particular BET protein-inhibiting, and preferably BRD4-inhibiting 3H-2,3-benzodiazepines of general formula (I), in which R1a, R1b, R1c, R2, R3, R4 and R5 have the meanings spec...  
WO/2015/121230A1
Described are bromodomain protein-inhibiting, especially BET protein-inhibiting, and preferably BRD4-inhibiting 9-substituted 2,3-benzodiazepines of general formula (I), in which R1a, R1b, R1c, R2, R3, R4, R5, and R6 have the meanings sp...  
WO/2015/109130A1
Provided herein are compounds useful for the treatment of HBV infection in a subject in need thereof, pharmaceutical compositions thereof, and methods of inhibiting, suppressing, or preventing HBV infection in the subject.  
WO/2015/103526A1
Disclosed are PARP-1 inhibitors, which can be 18 F-labeled for use as tracers in positron emission tomographic (PET) imaging. Further disclosed are methods of synthesis. Of the compounds synthesized, 2-[p-(2-Fluoroethoxy)phenyl]-1.3.10-t...  
WO/2015/080949A1
Disclosed are compounds of formula (I) (formula I),as antiviral agents, antineoplastic agents, pharmaceutical compositions comprising such compounds, and a method of use of these compounds, wherein X and Y are independently CH or N, o is...  
WO/2015/071393A1
Disclosed are compounds of Formula I, or pharmaceutically acceptable salts thereof, wherein W, X, Y, Z, R1, R2, R3, R4 and R5 are as described in this application, and methods of using said compounds in the treatment of cancer.  
WO/2015/058272A1
The present invention describes a process for selectively preparing (1H-1,2,4-triazol-1-yl)alkanols that can be used as synthesis intermediates and as pharmaceutical, veterinary and agrochemical active ingredients, and also the use of in...  
WO/2015/007896A1
The invention relates to a method for the synthesis of the compounds of formula (I) wherein X is a halogen atom. The molecules ML7 (X= I) and ML9 (X= Cl) are produced by said method.  
WO/2015/008218A3
A novel processes for the preparation of suvorexant (formula I), its related compounds and its intermediates that are simple, economical and commercially viable. (I)  

Matches 1 - 50 out of 3,471